Regenerative Market to be Worth $78.53 Billion by 2031

Regenerative Medicine Market Size, Share, Forecast, & Trends Analysis by Product (Gene Therapy, Stem Cell, PRP, CAR T Cell, Tissue Engineering) Application (Oncology, Cardiovascular, Neurology, Immunology) End User (Hospital, ASC) — Global Forecast to 2031

Meticulous Research^®—a leading global market research company, published a research report titled Regenerative Medicine Market Size, Share, Forecast, & Trends Analysis by Product (Gene Therapy, Stem Cell, PRP, CAR T Cell, Tissue Engineering) Application (Oncology, Cardiovascular, Neurology, Immunology) End User (Hospital, ASC) — Global Forecast to 2031.

According to this latest publication from Meticulous Research^®, the regenerative medicine market is projected to reach $78.53 billion by 2031 at a CAGR of 20% from 2024 to 2031.The growth of this market is driven by factors such as the increasing approvals of regenerative medicine, advances in regenerative medicine, the rising incidences of target diseases, the increasing applications of regenerative medicine in newer therapy areas, and increasing funding for the development of these medicines. However, the high cost of treatment and ethical concerns regarding stem cells may restrain growth.

Furthermore, the increasing demand for personalized medicine, the rising demand for organ transplants, and the increasing number of products in the pipeline are expected to create market growth opportunities. However, unfavorable reimbursement policies and manufacturing challenges are impeding the market’s growth.

Key Players

The key players operating in the regenerative medicine market are Novartis AG (Switzerland), Biogen Inc. (U.S.), AstraZeneca plc (U.K.), F. Hoffmann-La Roche AG (Switzerland), Integra Life Sciences (U.S.), Sarepta Therapeutics, Inc. (U.S.), Bayer AG (Germany), Amgen Inc. (U.S.), CORESTEMCHEMON Inc. (South Korea), Smith & Nephew plc (U.K.), GSK plc (U.K.), Takeda Pharmaceutical Company Limited (Japan), Astellas Pharma (Japan), Medtronic plc (Ireland), AbbVie Inc. (U.S.), Bristol Myers Squibb (U.S.), Cook Group Incorporated (U.S.), Pfizer Inc. (U.S.), Merck KGaA (Germany), and Vericel (U.S.).

Regenerative Medicine Market: Future Outlook

The regenerative medicine market is segmented by Product (Gene Therapy, Cell Therapy [Stem Cell Therapy {Autologous Therapy and Allogenic Therapy}, Platelet Rich Plasma Therapy, Cell-based Immunotherapy {CAR T Cell Therapy and Other Cell-based Immunotherapies}], and Tissue Engineering), Application (Cardiovascular Diseases, Ophthalmic Diseases, Oncology, Neurological Diseases, Immunology & Inflammation, Musculoskeletal Diseases, Dermatological Diseases, Other Applications), End User (Hospital & Clinics, Ambulatory Surgical Centers), and Geography. The study also evaluates industry competitors and analyzes the market at the global and regional levels.

Among the products covered in this report, the gene therapy segment is projected to register the highest growth rate during the forecast period of 2024–2031. This segment's large market share can be attributed to the increasing adoption of gene therapies for treating a variety of diseases, including cancer, immunodeficiency disorders, cystic fibrosis, and diabetes. Gene therapy involves adding new copies of a gene that is defective or replacing a faulty gene altogether. Advances in genetic engineering technology, such as CRISPR CAS, are further enhancing the field of gene therapy. CRISPR CAS enables precise genome alterations in less time. For instance, the U.K. government has approved the CRISPR–Cas9 gene editing therapy for treating sickle cell anemia. Manufacturers are also focusing on developing gene therapy products. According to the Alliance for Regenerative Medicine, as of the third quarter of 2023, 556 manufacturers in North America and 209 in Europe were developing gene therapy products.

Among the applications covered in this report, in 2024, the oncology segment is expected to account for the largest share of the regenerative medicine market. This segment’s large market share can be attributed to the high burden of cancer globally, increasing research focus on regenerative medicine for cancer treatment, increasing approvals of regenerative medicine products for oncology applications, a growing number of clinical trials in this field, and the increasing public-private funding dedicated to advancing oncology treatments. For instance, in March 2023, researchers at the University of California received a grant of USD 5.7 million from the California Institute of Regenerative Medicine to support advancements in stem cell therapy for cancer treatment.

Among the end users covered in this report, in 2024, the hospitals & clinics segment is expected to account for the larger share of the regenerative medicine market. This segment’s large market share can be attributed to the proliferation of public and private hospitals, the increasing prevalence of chronic diseases leading to higher hospital admissions, and the rising availability of regenerative medicine treatments in hospital settings. Additionally, the presence of reimbursement policies for regenerative medicine procedures at hospitals further contributes to the segment's largest share.

Geographic Review:

This research report analyzes major geographies and provides a comprehensive analysis of the market in North America (U.S. and Canada), Europe (Germany, France, U.K., Italy, Spain, Switzerland, Netherlands, Sweden, and Rest of Europe), Asia-Pacific (China, Japan, India, South Korea, Australia, and Rest of Asia-Pacific), Latin America (Brazil, Mexico, Rest of Latin America), and the Middle East & Africa.

Among all the regions studied covered in this report, the market in Asia-Pacific is projected to register the highest growth rate during the forecast period. The growth of this regional market is driven by supportive government initiatives aimed at promoting regenerative medicine and increasing funding for research initiatives. Governments in countries such as India, Australia, and South Korea are actively providing research grants to support the advancement of regenerative medicine, creating opportunities for market growth. For instance, the Department of Biotechnology in India allocated a fund of USD 9.35 million over four years from 2019 to 2022 to promote research in this field.

Furthermore, the cost-effectiveness of stem cell therapy treatment in countries like India, compared to North America and Europe, is attracting medical tourists and driving the demand for regenerative medicine. Medical Tourism Corporation in India reports that the cost of stem cell therapy in the country is approximately 25% lower than in Western countries, making it a more affordable option for patients seeking such treatments.

Download Sample Report Here @ https://www.meticulousresearch.com/download-sample-report/cp_id=5864

Key questions answered in the report-

Which are the high-growth market segments in terms of product, application, end user, and region/country?
What was the historical market size of the regenerative medicine market globally?
What are the market forecasts and estimates for the period 2024–2031?
What are the major drivers, restraints, challenges, opportunities, and trends in the regenerative medicine market?
Who are the major players in the regenerative medicine market?
What is the competitive landscape like, and who are the market leaders in the regenerative medicine market?
What are the recent developments in the regenerative medicine market?
What are the different strategies adopted by the major players in the regenerative medicine market?
What are the geographical trends and high growth regions/countries?

Contact Us:
Meticulous Research®
Email- sales@meticulousresearch.com
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research